Relievant Medsystems
2688 Middlefield Road
Suite A
Redwood City
California
94063
United States
Tel: 650-368-1000
Website: http://www.relievant.com/
Email: info@relievant.com
31 articles about Relievant Medsystems
-
Boston Scientific Closes Acquisition of Relievant Medsystems, Inc.
11/17/2023
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Relievant Medsystems Inc.
-
Relievant Medsystems Announces Positive Coverage Policy for the Intracept Procedure from Anthem Blue Cross and Blue Shield
10/3/2023
Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, announced that Anthem Blue Cross and Blue Shield has established favorable coverage for the Intracept® Procedure.
-
Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.
9/19/2023
Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company.
-
Relievant Medsystems Announces Pooled Analysis Demonstrating the Intracept Procedure Significantly Reduces Low Back Pain-related Healthcare Utilization
9/12/2023
Relievant Medsystems announced the publication of a pooled analysis from three prospective clinical trials that demonstrates the impact of the company’s Intracept® Procedure on significantly reducing the long-term utilization of additional treatments for low back pain.
-
Relievant Medsystems Announces Pooled 4-Year Outcomes Validating Long-Term Effectiveness of the Intracept Procedure
7/20/2023
Relievant Medsystems announced the presentation of four-year pooled results from two prospective clinical trials that further demonstrate the safety, effectiveness and long-term durability of the Intracept® Procedure for patients with vertebrogenic pain.
-
Relievant Medsystems Introduces Next-Generation Access Instruments to Advance Intracept Procedure for Chronic Vertebrogenic Low Back Pain
7/14/2023
Relievant Medsystems today announced the release of next-generation Intracept ® Access Instruments.
-
Relievant Medsystems Announces Pooled Three-Year Outcomes from Intracept Procedure that Demonstrate Long-Term Pain Relief and Reduced Opioid Use in Chronic Vertebrogenic Low Back Pain Patients
6/15/2023
Relievant Medsystems announced the publication of three-year pooled results from two prospective clinical trials that further validate the safety, effectiveness and long-term durability of the Intracept® Procedure for patients with vertebrogenic pain.
-
Relievant Medsystems Announces Highest Quality of Evidence Ranking for Basivertebral Nerve Ablation in ASPN Back Guideline for Interventional Low Back Pain Treatments
1/5/2023
Relievant Medsystems announced that basivertebral nerve ablation received a Grade A Quality of Evidence Ranking with High Level of Certainty Regarding Net Benefit in the American Society of Pain & Neuroscience Evidence-Based Clinical Guideline of Interventional Treatments for Low Back Pain.
-
Relievant Medsystems Announces Updated Policy Statement and Guideline for Basivertebral Nerve Ablation from the International Society for the Advancement of Spine Surgery
11/8/2022
Relievant Medsystems announced that the International Society for the Advancement of Spine Surgery has published an updated Policy Statement and Literature Review of Intraosseous Basivertebral Nerve ablation in the October issue of the International Journal of Spine Surgery.
-
Relievant Medsystems Announces Publication of ASPN Guidelines on the Diagnosis and Treatment of Vertebrogenic Low Back Pain with Basivertebral Nerve Ablation
9/20/2022
Relievant Medsystems announced that the American Society of Pain & Neuroscience multidisciplinary work group of leading experts have assigned a Grade A evidence rating for basivertebral nerve ablation and developed Best Practice Guidelines on the Diagnosis and Treatment of Vertebrogenic Pain with BVN ablation.
-
Relievant Medsystems Announces New Category I CPT Codes for Intracept® Procedure
1/3/2022
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain, announced that new Category I Current Procedural Terminology codes for the Intracept Procedure are in effect as of January 1, 2022.
-
Relievant Medsystems Announces Publication of New INTRACEPT Trial Data Demonstrating Long-Term Relief for Chronic Low Back Pain 24 Months Post-Procedure
11/30/2021
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced 24-month results from a Level 1, prospective, randomized, multi-center trial (INTRACEPT) that further validate the safety, effectiveness, and durability of the Intracept® Procedure for patients with vertebrogenic CLBP.
-
Relievant Medsystems Announces Appointment of Dave Amerson to Board of Directors
7/1/2021
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain, announced the appointment of Dave Amerson to the Company’s Board of Directors.
-
UPDATE -- Relievant Medsystems Names Tyler Binney President and CEO
5/10/2021
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain, announced the appointment of Tyler Binney as President and Chief Executive Officer.
-
Relievant Medsystems Names Tyler Binney President and CEO
5/10/2021
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today the appointment of Tyler Binney as President and Chief Executive Officer. Mr. Binney will also join Relievant’s Board of Directors. Arthur Taylor, who previously held the CEO position on an interim basis, will return to his role on the Board of Directors.
-
Relievant Medsystems Launches Intracept.com Patient Education WebsiteLaunch Reflects Substantial Patient Interest in the Intracept® Procedure
1/12/2021
Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain, announced the launch of Intracept.com – a new website helping educate patients regarding the Intracept Procedure.
-
Relievant Medsystems Announces $70M Financing to Accelerate U.S. Commercialization of Intracept Procedure
10/29/2020
Financing to build on significant 2020 commercial momentum following the publication of 5-year data demonstrating the long-term clinical benefits of the Intracept Procedure
-
Relievant Announces Positive 12-Month Intracept Effectiveness Study Results From Community Based Practices
10/22/2020
Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced the North American Spine Society Journal publicationi of results from an effectiveness study showing that the significant improvements in function and pain initially reported at an interim analysis of three monthsii following the Intracept Procedure remained significant through one year.
-
Relievant Announces Publication of 5-Year Data Demonstrating Long Term Clinical Benefits of the Intracept Procedure in Chronic Low Back Pain Patients
6/8/2020
Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced European Spine Journal publication of long-term data from the Level I SMART trial showing durability of improvements in pain and function beyond 5 years for patients treated with the Intracept procedure. The recently published long-term study i is a single-arm, open-label, prospective follow-up of 100 US pati
-
Relievant Announces Publication of Positive Outcomes in 12-Month SMART Sham RCT
2/9/2018
The SMART Trial is a Level 1, randomized, sham-controlled, double-blind clinical trial for chronic low back pain whose rigor, size, and clinical outcomes are unprecedented in the field of spine care.